Impress: improved methylation profiling using restriction enzymes and smmip sequencing, combined with a new biomarker panel, creating a multi-cancer detection assay

HIGHLIGHTS

• What: In this study, the proof-of-principle of the biomarker assay combining the new IMPRESS technique and the biomarker panel, is described. For this selection, the authors started with the top 200 best performing smMIP targets, for which the authors aimed to design ddPCR primers and probes.
• Who: Janah Vandenhoeck from the Sample collection and processing Control samplesLambda phage DNA was purchased from Thermo Fisher Scientific (USA). Human methylated and non-methylated (WGA) DNA was purchased from Zymo Research (USA). Four cancer cell lines were provided by the Centre for Oncological Research (CORE, Antwerp . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.